NCT00291473已完成1 期
Safety and Immunogenicity of Cholesterol-Bearing Hydrophobized Pullulan HER2 Protein 146 (CHP-HER2) and NY-ESO-1 Protein (CHP-NY-ESO-1) in Combination With OK-432 in HER2- and/or NY-ESO-1-Expressing Cancers
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 9
- 试验地点
- 2
- 主要终点
- adverse events
研究概览
简要总结
Mixed cancer vaccines, CHP-HER2 protein and CHP-NY-ESO-1 protein, are to be studied to evaluate the safety and immune responses in patients who are positive either or both antigens. Nine patients will be enrolled, who are refractory to standard therapies for cancer or at high risk to relapse. CHP-HER2 and CHP-NY-ESO-1 are subcutaneously given on bimonthly basis, together with OK-432(Picibanil) as an immunoadjuvant. Six doses will be given. Toxicity profiles will be monitored, and antigen specific humoral anad T cell responses will be described.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histological confirmation of cancer.
- •HER2 expression in tumor cells scored as 1+ or more which should be confirmed by IHC using at least two antibodies (archived issue; see Appendix 1 and Reference 1 for methodology).
- •or NY-ESO-1 expression by reverse transcriptase and polymerase chain reaction (RT-PCR) analysis (Appendix 2), preferably, or immunohistochemistry
- •Patients must
- •are at high risk of recurrence, more than 25% of probability, after complete resection or even after post-operative adjuvant treatment, and effective adjuvant therapy is not available or refused; or
- •have metastatic disease, and treatment has failed, or in the situation where effective therapy is not available, or has been refused.
- •Complete recovery from surgery (at least 4 weeks).
- •Laboratory values within the following limits:
- •Hemoglobin 9.0 g/dL or more, or 10.0 g/dL or more if <50 kg Neutrophil count >1.5 x 109/L Lymphocyte count >0.5 x 109/L Platelet count >100 x 109/L Serum creatinine ≤ 1.8 mg/dL Serum bilirubin ≤ 2 mg/dL
- •Performance status > 70 (Karnofsky Scale) and life expectancy >3 months.
- •Age 18 years or more.
排除标准
- •Clinically significant heart disease (NYHA Class III or IV).
- •Cardiac dysfunction; less than 50% of ejection fraction by echocardiogram.
- •Immunodeficiency disease.
- •Other serious illnesses, eg, serious infections requiring antibiotics, bleeding disorders.
- •Previous bone marrow or stem cell transplant.
- •Metastatic disease to the central nervous system, unless treated and stable.
- •known HIV antibody positivity.
- •Anaphylactic reaction to previous vaccination.
- •Hypersensitivity to penicillin
- •Chemotherapy, any type of radiation therapy, or immunotherapy within 4 weeks before study entry (6 weeks for nitrosoureas).
- •Concomitant treatment with steroids. Topical or inhalational steroids are permitted.
- •Participation in any other clinical trial involving another investigational agent within 4 weeks prior to enrollment.
- •Pregnancy or nursing .
- •Refusal, by women of childbearing potential, to use medically acceptable means of contraception.
- •Mental impairment that may compromise the ability to give informed consent.
- •Lack of availability for immunological and clinical follow-up assessment.
结局指标
主要结局
adverse events
次要结局
- immune responses including HER2 and NY-ESO-1 specific IgG and T cells
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Safety Study of NY-ESO-1 Protein Vaccine to Treat Cancer Expressing NY-ESO-1NeoplasmsNCT00106158Ludwig Institute for Cancer Research9
已完成
1 期
Safety of and Immune Response to Prime/Boost Vaccine Regimens in Healthy, HIV-1 Uninfected, Ad5 Seronegative AdultsHIV InfectionsNCT00961883HIV Vaccine Trials Network80
已完成
2 期
Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCGBladder CancerNCT02015104National Cancer Institute (NCI)32
Unknown
2 期
Phase II Study of S-488410 to Treat Non-small Cell Lung CancerCarcinoma, Non-Small-Cell LungNCT01592617Shiga University45
已完成
1 期
clinical trial of CHP-HER2 cancer vaccine with immuno-adjuvant, OK-432, for advanced breast cancerResected locally-advanced breast cancerJPRN-UMIN000001286Mie University, University of Ocupational and Environmental Health, Nagasaki University, National Hospital Organization Saga National Hospital, Hamamatsu Medical Center20